Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33125888.
- Also identified by DOI 10.1016/j.cell.2020.10.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeting cancer neoantigens generated by tumor-exclusive somatic mutations is an attractive yet challenging strategy for the robust and specific elimination of tumor cells by cellular immunotherapy. In this issue of Cell, Wells et al. describe a consortium-based approach to optimize bioinformatics pipelines to sensitively and accurately predict immunogenic neoantigens from next-generation sequencing data.
Medical subject headings
- Antigens, Neoplasm
- Neoplasms